Dyadic Reports Second Quarter 2017 Financial Results
JUPITER, Fla., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June 30, 2017.
BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS
Cash, cash equivalents and investment grade securities, including interest receivable at June 30, 2017, was approximately $45.6 million
BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS
Cash, cash equivalents and investment grade securities, including interest receivable at June 30, 2017, was approximately $45.6 million